Compare Avantis International Small Cap Value ETF (AVDV) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Moderna, Inc. — how do they compare? Avantis International Small Cap Value ETF trades at $110.5, while Moderna, Inc. trades at $63.85 (market cap $25.42B). The key difference: Avantis International Small Cap Value ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| AVDV | MRNA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $81.80 |
52-Week Low | $83.91 | $22.36 |
Market Cap | — | $25.42B |
Enterprise Value | — | $21.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $110.28, up 0.75% today, with a bullish technical signal from moving averages but caution from overbought oscillators. The stock shows strength near resistance at $110, supported by positive media coverage highlighting international small-cap value performance and a forthcoming dividend. Recent news notes a 21% return since November 2025, driven by commodity exposure that has since cooled.
Outlook remains positive due to strong momentum and dividend yield, but risks include overbought conditions and reliance on international markets. Investors should weigh technical indicators against fundamental growth prospects in developed ex-US small caps.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
